Overview
- 5 inspections across 5 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2023-03-24.
At a glance
Inspections
5
Sites
5
Observations
1
Career since
Aug 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Sarepta Therapeutics Inc | 24 Mar 2023 | Biologics | View 483 → |
| Catalent Maryland Inc | 10 Mar 2023 | Biologics | On file |
| Catalent Maryland, Inc. | 24 Feb 2023 | Biologics | |
| Biomarin Pharmaceutical Inc. | 9 Dec 2022 | Biologics | On file |
| Uniqure Inc | 19 Aug 2022 | Biologics | On file |
Sites inspected
Sarepta Therapeutics IncAndover, United States1 insp.
Catalent Maryland IncHarmans, United States1 insp.
Catalent Maryland, Inc.Baltimore, United States1 insp.
Biomarin Pharmaceutical Inc.Novato, United States1 insp.
Uniqure IncLexington, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Sukyoung Sohn2 shared
Kevin J Matthews1 shared
Grace I Cortesini1 shared
Lilia L Bi1 shared
Viviana R Ramirez1 shared
Ou Ma1 shared
Christine Harman1 shared
Scott T Ballard1 shared
Kula N Jha1 shared
Alifiya H Ghadiali1 shared
Full investigator report
Get the verbatim findings behind Emmanuel Adu-Gyamfi's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site